Bayer’s $7.25 Billion Roundup Deal Faces Court Challenge
A proposed $7.25 billion settlement designed to resolve tens of thousands of lawsuits alleging that Bayer’s Roundup weedkiller causes cancer may face a delay after a Missouri state court judge signaled concerns about ongoing jurisdictional disputes. The development represents the latest twist in one of the largest mass-tort settlements in U.S. legal history and could slow Bayer’s efforts to bring years of Roundup litigation closer to a resolution.
The litigation involves claims against Bayer and its Monsanto subsidiary, which Bayer acquired in 2018. Plaintiffs allege that prolonged exposure to Roundup, whose active ingredient is glyphosate, caused them to develop non-Hodgkin lymphoma and other forms of cancer. Bayer has consistently denied those allegations, maintaining that decades of scientific research and regulatory reviews support the safety of glyphosate when used as directed.
The proposed settlement seeks to resolve approximately 65,000 pending claims in state and federal courts. Bayer and attorneys supporting the agreement have described it as a comprehensive resolution that would compensate current claimants and address future litigation risks. If approved, it would rank among the largest class-action and mass-tort settlements ever negotiated in the United States.
In March, Missouri Circuit Judge Timothy Boyer granted preliminary approval to the settlement and scheduled a final approval hearing for July 9. However, Boyer recently indicated that he may postpone that hearing because of ongoing disputes regarding whether the settlement should be reviewed in Missouri state court or federal court.
The jurisdictional battle has become a central issue in the case. Bayer and attorneys supporting the settlement argue that the agreement should remain in Missouri state court, where approval proceedings have been moving forward on an accelerated schedule. Opponents of the settlement, however, contend that the case belongs in federal court and should be reviewed by a federal judge who has previously expressed concerns about aspects of the proposed agreement.
The dispute intensified after objecting plaintiffs temporarily succeeded in transferring the case to federal court. That transfer was short-lived. Earlier this month, U.S. District Judge Henry Edward Autrey sent the settlement proceedings back to Missouri state court, ruling that the objecting plaintiffs lacked authority to remove the case to federal court. The plaintiffs have since appealed that decision and continue to seek federal court review.
Judge Boyer noted that the uncertainty created by the federal proceedings may justify delaying the final approval hearing. He requested additional input from the parties and indicated that he could either schedule another status conference or issue a revised timetable after reviewing their submissions.
Supporters of the settlement insist that any delay would likely be modest. Bayer stated that a reasonable postponement would not materially affect the approval process. Attorney Chris Seeger, who represents claimants supporting the settlement, likewise expressed confidence that the agreement remains on track despite procedural complications.
Opponents continue to challenge the fairness of the proposal. Some objectors argue that the settlement does not adequately protect cancer victims and improperly attempts to impose terms on individuals who may develop cancer in the future. Others have questioned whether a Missouri state court has authority to approve a nationwide resolution affecting claimants in multiple jurisdictions. Additional objections are expected before any final approval hearing takes place.
The Roundup litigation has been one of Bayer’s most significant legal and financial challenges since its acquisition of Monsanto. The company has already spent billions resolving earlier claims and continues to face substantial litigation exposure. While Bayer maintains that scientific evidence does not support allegations that Roundup causes cancer, juries in several cases have previously awarded significant verdicts to plaintiffs, increasing pressure on the company to seek a broader settlement strategy.
Ultimately, the proposed settlement remains alive but faces another procedural hurdle. Whether Judge Boyer delays the July approval hearing or proceeds as scheduled, the litigation will continue to be closely watched by plaintiffs, investors, and legal experts. The outcome could determine whether Bayer finally secures a sweeping resolution to thousands of remaining Roundup cancer claims or faces additional delays and challenges in one of the largest product-liability disputes in modern U.S. history.
⚖️ Key Legal Outcomes
- Judge Timothy Boyer is considering delaying the July 9 final approval hearing.
- The settlement seeks to resolve approximately 65,000 Roundup cancer claims.
- A federal judge recently returned the case to Missouri state court.
- Objecting plaintiffs have appealed and continue to push for federal court review.
- Bayer maintains that Roundup’s glyphosate ingredient does not cause cancer.
📌 Why It Matters
- Involves one of the largest proposed mass-tort settlements in U.S. history.
- Could affect compensation for tens of thousands of cancer claimants.
- Highlights ongoing disputes over federal versus state court authority.
- Demonstrates the continuing legal fallout from Bayer’s Monsanto acquisition.
- The approval decision could shape future nationwide mass-tort settlements.
RELATED:
